Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
CA 2487811 A1 · Owner: Holm, Per Sonne · Inventors: Holm, Per Sonne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of a virus preferably an adenovirus, for the , production of a medicament or for replication in cells. Said virus is replication-deficient in cells which do not , contain YB-1 in the core while coding for an oncogene or oncogene product especially an oncogene , protein, which transactivates at least one viral gene preferably an , adenoviral gene, said gene being selected among the group comprising E1B55kDa E4orf6, E4orf3, and E3ADP. The , oncogene protein represents the viral oncogene protein E1A which is mutated for , example. Said medicament , is used particularly for treating tumors showing multiple resistance against cytostatic drugs.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 27, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.